Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Entera Bio Ltd.NASDAQ: ENTX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets broadly unchanged from a year ago
Other current assets stood at $8.05M at the end of Q1 FY2026, down 1.5% from a year earlier and up 3774.0% from the prior quarter.
Context
- Other current assets amounted to 61.3% of total assets at the end of Q1 FY2026, up 23.5 pp from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -1.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- (219K) USD
- Year-over-year change
- -217.7%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (219K) | -217.7% |
| FY2024 | 2024-12-31 | 186K | -21.8% |
| FY2023 | 2023-12-31 | 238K | -19.0% |
| FY2022 | 2022-12-31 | 294K | +15.7% |
| FY2021 | 2021-12-31 | 254K | — |
Other Current Assets vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 other current assets of $8.05M is the highest of the 10 companies compared; the peer median is $1.77M.
- Its year-over-year change of -1.5% is the 2nd highest of 9, against a peer median of -17.9%.
- Other current assets amounts to 61.3% of total assets for ENTX, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.05M | -1.5% | — | 61.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $3.93M | +184.6% | +181.7% | 5.9% |
| Mar 2026 | $3.57M | -27.7% | +43.1% | 2.7% | |
| Mar 2026 | $2.59M | -17.1% | -3.4% | 1.0% | |
| Mar 2026 | $2.04M | -15.9% | — | 1.1% | |
| Mar 2026 | $1.77M | -37.8% | -37.7% | 1.5% | |
| Mar 2026 | $1.44M | -7.0% | -21.5% | 2.4% | |
| Apr 2026 | $950K | -18.7% | +149.3% | 6.4% | |
| Mar 2026 | $367.51K | -47.7% | +36.9% | 1.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ENTX) | $1.77M | -17.9% | +36.9% | 1.5% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.